Clinical trials: Fatty Acid Metabolism
Major Depression, Cancer
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions…
- Conditions
- Major Depression, Cancer, Diabetes, Cardiovascular Diseases
- Trial name
- NCT01803711
- Testing
- Desvenlafaxine, Omega 3 Fatty acids
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UConn Health
Diabetes Mellitus, Type 1, Hypoglycemia
Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients
The investigator propose to test the safety and efficacy of a regimen that combines Omega-3 Fatty Acids and Vitamin D in a design that considers timing and duration of administration in relation to their effects and predicted…
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Diabetes Mellitus, Diabetes, Autoimmune
- Trial name
- POSEIDON (NCT03406897)
- Testing
- Cholecalciferol, Omega 3 fatty acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Rodolfo Alejandro
Type 2 Diabetes, Hypertension
Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
Insulin resistance has been implicated as the central pathogenetic feature of cardiovascular risk factor cluster that includes hypertension, impaired glucose tolerance, diabetes, dyslipidemia, and hemostatic disorders.
- Trial name
- NCT00738023
- Testing
- Rosiglitazone, Normal saline 0.9%, Intralipid 20%
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Emory University
Polycystic Ovarian Syndrome, Obesity
Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS
The Investigators will measure hepatic glucose and fat metabolism in obese girls with Polycystic Ovarian Syndrome (PCOS) and hepatic steatosis (HS) after taking 4 weeks of an essential amino acid (EAA) supplement or placebo and…
- Conditions
- Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
- Trial name
- ORANGE (NCT03717935)
- Testing
- Essential Amino Acid (EAA) Supplement
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus
Free Fatty Acids and Vascular Function in Subjects With Diabetes
This study will test the hypothesis that reduction in release of free fatty acids from adipocytes will restore insulin-mediated endothelium-dependent vasodilation and skeletal muscle glucose metabolism in subject with type 2…
- Trial name
- NCT00153179
- Testing
- acipimox
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Obesity
Effect of Fibre Products on Appetite and Weight
This study explores the nutritional effects of fibre. Short chain fatty acid(SCFA), such as propionate, are produced through the fermentation of fibre in the bowel.
- Trial name
- NCT00750438
- Testing
- Propionate ester, Inulin, Cellulose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Infants of Diabetic Mothers
Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial
Gestational diabetes mellitus (GDM) affects as many as 14% of women in the United States. Furthermore, the number of pregnant women with pregestational diabetes mellitus (PGDM) is also increasing, mainly due to an increase in the…
- Trial name
- FAEE-IDM (NCT02308735)
- Testing
- N/A - No intervention
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Obesity, Insulin Resistance
Intervention Study With Omega-3 Fatty Acids for Weight Loss and Insulin Resistance in Adolescents
The purpose of this study is to evaluate if a supplement containing omega-3 long chain polyunsaturated fatty acids for three months reduce obesity and insulin resistance to obese adolescents if administered together with a…
- Trial name
- O3WLIRADOL (NCT01456221)
- Testing
- Omega3 and an hypocaloric diet., Sunflower oil with an hypocaloric diet.
- Where
- Mexico
- Volunteers
- 366 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Diabetes Mellitus, Type II
Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Type 2 Diabetes Mellitus (T2DM) is a disease that interferes with the body's proper production and use of insulin, a hormone needed to convert sugar into usable energy.
- Trial name
- T2DM (NCT00577590)
- Testing
- Metformin, Rosiglitazone, Lovaza
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Washington University School of Medicine
Obesity, Inflammation
Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment
Comparative, randomized, placebo-controlled, single-centre, single-blind clinical trial to assess the effectiveness of providing additional DHA omega-3 fatty acids supplements to increase the levels of pro-resolving and…
- Trial name
- NCT01865448
- Testing
- Omega-3 DHA
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Protein Supplies SL
High Triglycerides, Hypercholesterolemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication.
- Conditions
- High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00833976
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Diabetes, Hypertension
FFA Hypertension and Inflammation in Lean and Obese Subjects
Although a large number of obese patients develop high blood pressure, the cause is unknown. The purpose of this study is to look at the effect of high fatty acids (a type of fat) in the development of high blood pressure in…
- Conditions
- Diabetes, Hypertension, Obesity
- Trial name
- FFAADA (NCT00721617)
- Testing
- Intralipid 20%, Normal Saline, Oral fat load
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Emory University
Obesity, Overweight
Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)
The purpose of this study is to better understand the different ways our bodies burn fat which may be important for obesity, diabetes, and cardiovascular disease.
- Conditions
- Obesity, Overweight, Metabolic Diseases
- Trial name
- MagellanII (NCT01616082)
- Testing
- Low Calorie Diet (LCD), Phentermine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- AdventHealth Translational Research Institute
Healthy
Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids
Background: As the main alternative fuel to glucose for the brain, increased plasma ketones could potentially help compensate for brain glucose hypometabolism occurring during aging.
- Trial name
- NCT02410161
- Testing
- alpha-linolenic acid-rich supplement
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease.
- Trial name
- NCT03938246
- Testing
- TVB-2640 25 mg (US), TVB-2640 50 mg (US), TVB-2640 50 mg (China)
- Where
- 23 sites in United States, China
- Volunteers
- 142 people
- Sponsor
- Sagimet Biosciences Inc.
Hypertriglyceridemia
Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia
The purpose of this study is to evaluate the efficacy and safety of Omacor (omega-3-acid ethyl esters) combined with atorvastatin for lowering non-high-density lipoprotein cholesterol (non-HDL-C) in hypertriglyceridemic subjects.
- Trial name
- NCT00435045
- Testing
- Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin, atorvastatin
- Volunteers
- 245 people
- Sponsor
- GlaxoSmithKline
Obesity, Leptin Resistance
Effect of Increased Free Fatty Acids on Leptin Function
Obese people have elevated levels of the hormone leptin. Despite this, they seem to be resistant to the effects of this hormone, which usually regulates appetite and energy expenditure.
- Trial name
- NCT01520454
- Testing
- Saline, Intralipid, Water
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Prediabetes, Obesity
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk.
- Trial name
- NCT02104739
- Testing
- Exenatide, Saxagliptin, Exenatide extended-release (ER)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Type 2 Diabetes
The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes
There is evidence that inhibition of FFA-release by acipimox is associated with a significant decrease in myocardial lipid content (MYCL) as well as the ejection fraction (as a marker of systolic left ventricular function) in…
- Trial name
- HYPOTESIS (NCT01980524)
- Testing
- acipimox
- Where
- Austria
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Hypertriglyceridemia
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.
- Trial name
- MARINE (NCT01047683)
- Testing
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
- Where
- 60 sites in United States, Denmark and 9 more
- Volunteers
- 229 people
- Sponsor
- Amarin Pharma Inc.